Oppenheimer & Co. Inc. acted as exclusive financial advisor to FarmboxRx, a leading health plan member engagement platform that improves member health outcomes via customizable nutrition solutions and health literacy.
Pyx Health is a health plan member engagement company focused on addressing health-related social and physical needs to impact outcomes for at-risk populations.
The acquisition brings together two mission-driven organizations dedicated to improving health outcomes for at-risk populations. By combining FarmboxRx’s nutrition-based services with Pyx Health’s mentor-driven engagement model, the joint platform will deliver personalized, scalable support to address key social determinants of health.
The acquisition was announced alongside a $47.5M investment from S2G investments, a multi-stage investment firm focused on scaling solutions across food and agriculture, energy, and oceans, in strategic partnership with TT Capital Partners, which first invested in Pyx Health in 2023.
This transaction is the third Healthcare M&A transaction that Oppenheimer has advised on in the last two months.

Don Ritucci
Title:Managing Director, Head of Healthcare Mergers & Acquisitions

Matt Jackson
Title:Managing Director, Head of Healthcare Services

Rishi Soni
Title:Executive Director
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2025 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 8039208.1